JPMorgan Equity Premium Income ETF vs Revvity Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.75 (market cap $45.55B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 2.7× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 57 Days and Revvity Inc for 12 Days on average.
| JEPI | RVTY | |
|---|---|---|
Market Cap | $45.55B | $16.98B |
Volume | 3,820,809 | 1,456,900 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $157.36 |
52-Week Low | $55.29 | $82.26 |
Typical Hold Time | 57 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.77, up 0.57% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend payments with recent distributions of $0.34-$0.37, positioning it as an income-focused vehicle. Recent news highlights JEPI's role in retirement income strategies and its appeal to investors seeking monthly distributions from covered call strategies.
The outlook remains cautious given the bearish technical setup, though the income generation capability provides downside cushion. Key risks include market volatility impacting the covered call strategy and interest rate sensitivity. Institutional interest continues with recent position increases, supporting the ETF's income-oriented appeal in uncertain markets.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →